<DOC>
	<DOCNO>NCT01182753</DOCNO>
	<brief_summary>The study prospective randomise clinical phase III trial . Proton therapy gold standard treatment low intermediate grad chondrosarcoma skull base . However , high-LET beam carbon ion theoretically offer biologic advantage enhance biologic effectiveness slow-growing tumor . Up impossible compare two different particle therapy , i.e . proton carbon ion therapy directly . The aim study find , whether biological advantage carbon ion therapy mention also clinically confirm .</brief_summary>
	<brief_title>Trial Proton Versus Carbon Ion Radiation Therapy Patients With Low Inter-mediate Grade Chondrosarcoma Skull Base</brief_title>
	<detailed_description>The study prospective randomise clinical phase III trial . The trial carry Heidelberger Ionenstrahl-Therapie ( HIT ) centre monocentric trial . Proton therapy gold standard treatment low intermediate grad chondrosarcoma skull base . However , high-LET beam carbon ion theoretically offer biologic advantage enhance biologic effectiveness slow-growing tumor . Up impossible compare two different particle therapy , i.e . proton carbon ion therapy directly . The aim study find , whether biological advantage carbon ion therapy mention also clinically confirm . Patients skull base chondrosarcoma randomise either proton carbon ion radiation therapy . As standard , patient undergo non-invasive , rigid immobilization target volume definition carry base CT MRI data . The biologically isoeffective target dose PTV carbon ion treatment 60 Gy E ± 5 % 70 Gy E ± 5 % ( standard dose ) proton therapy respectively . The 5 year local-progression free survival ( LPFS ) rate analyse primary end point . Overall survival , progression free metastasis free survival , pattern recurrence , local control rate morbidity secondary end point . Plan quality also matter interest .</detailed_description>
	<mesh_term>Chondrosarcoma</mesh_term>
	<criteria>Karnofsky Performance Score ≥60 % Age &gt; 18 year &lt; 80 year Informed consent sign patient Histological confirmation low/ intermediate grade chondrosarcoma infiltration skull base . Inability understand aim study , inform consent Prior RT skull base region Other malignancy diseasefree interval &lt; 5 year ( except precancerous lesion ) Participation another trial Pregnancy Simultaneous CHT Immunotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Chondrosarcoma</keyword>
	<keyword>Radiation</keyword>
	<keyword>carbon ion</keyword>
</DOC>